Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034334356> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2034334356 endingPage "127" @default.
- W2034334356 startingPage "126" @default.
- W2034334356 abstract "The influence of various statins on low-density-lipoprotein (LDL)-particle phenotype has been reportedly trivial or moderate. We assessed the effect of rosuvastatin (the newest statin available) on the LDL subfraction profile in patients with primary hyperlipidemia. One hundred and twenty patients with primary hyperlipidemia without evidence of cardiovascular disease were randomized to therapeutic lifestyle modification (‘control’ group, N = 60) or therapeutic lifestyle modification plus rosuvastatin 20 mg/day (N = 60). Laboratory evaluation was performed at baseline and 12 weeks post-treatment. LDL subfraction analysis was carried out electrophoretically using of high-resolution 3% polyacrylamide gel tubes and the Lipoprint LDL System. Rosuvastatin induced a redistribution of LDL-cholesterol from small-dense LDL particles to large-buoyant ones and increased the mean LDL particle size. This beneficial effect was observed only in patients with baseline triglyceride levels ≥ 150 mg/dl (mean LDL particle size 255 ± 7 Ǻ vs 260 ± 5 Ǻ, P < 0.01), whereas the LDL subfraction profile was not altered in those with triglyceride levels < 150 mg/dl. Stepwise multivariate linear regression analysis revealed that baseline triglyceride levels (R2 = 0.29, P = 0.001) followed by baseline insulin resistance as assessed by the HOmeostasis Model Assessment (HOMA) (R2 = 0.25, P = 0.001) were independently associated with the rosuvastatin-induced increase in the mean LDL particle size. In conclusion, rosuvastatin at 20 mg/day favorably modified the relative distribution of LDL-cholesterol distribution on LDL subfractions as well as on the mean LDL particle size in patients treated for primary dyslipidemia. Baseline triglyceride levels as well as baseline HOMA-index were found to be the major predictors of this beneficial action of rosuvastatin." @default.
- W2034334356 created "2016-06-24" @default.
- W2034334356 creator A5013437604 @default.
- W2034334356 creator A5026598714 @default.
- W2034334356 creator A5032218366 @default.
- W2034334356 creator A5039377625 @default.
- W2034334356 creator A5056379080 @default.
- W2034334356 creator A5059820737 @default.
- W2034334356 creator A5068703263 @default.
- W2034334356 creator A5074905198 @default.
- W2034334356 date "2008-05-01" @default.
- W2034334356 modified "2023-09-23" @default.
- W2034334356 title "HIGH-DENSITY LIPOPROTEIN SUBCLASSES IN PATIENTS WITH OR WITHOUT THE METABOLIC SYNDROME" @default.
- W2034334356 doi "https://doi.org/10.1016/s1567-5688(08)70510-5" @default.
- W2034334356 hasPublicationYear "2008" @default.
- W2034334356 type Work @default.
- W2034334356 sameAs 2034334356 @default.
- W2034334356 citedByCount "0" @default.
- W2034334356 crossrefType "journal-article" @default.
- W2034334356 hasAuthorship W2034334356A5013437604 @default.
- W2034334356 hasAuthorship W2034334356A5026598714 @default.
- W2034334356 hasAuthorship W2034334356A5032218366 @default.
- W2034334356 hasAuthorship W2034334356A5039377625 @default.
- W2034334356 hasAuthorship W2034334356A5056379080 @default.
- W2034334356 hasAuthorship W2034334356A5059820737 @default.
- W2034334356 hasAuthorship W2034334356A5068703263 @default.
- W2034334356 hasAuthorship W2034334356A5074905198 @default.
- W2034334356 hasConcept C126322002 @default.
- W2034334356 hasConcept C134018914 @default.
- W2034334356 hasConcept C185592680 @default.
- W2034334356 hasConcept C2776839432 @default.
- W2034334356 hasConcept C2778096610 @default.
- W2034334356 hasConcept C2778163477 @default.
- W2034334356 hasConcept C2778913445 @default.
- W2034334356 hasConcept C2779091943 @default.
- W2034334356 hasConcept C2779620165 @default.
- W2034334356 hasConcept C2780072125 @default.
- W2034334356 hasConcept C2780499067 @default.
- W2034334356 hasConcept C511355011 @default.
- W2034334356 hasConcept C555293320 @default.
- W2034334356 hasConcept C62746215 @default.
- W2034334356 hasConcept C71924100 @default.
- W2034334356 hasConceptScore W2034334356C126322002 @default.
- W2034334356 hasConceptScore W2034334356C134018914 @default.
- W2034334356 hasConceptScore W2034334356C185592680 @default.
- W2034334356 hasConceptScore W2034334356C2776839432 @default.
- W2034334356 hasConceptScore W2034334356C2778096610 @default.
- W2034334356 hasConceptScore W2034334356C2778163477 @default.
- W2034334356 hasConceptScore W2034334356C2778913445 @default.
- W2034334356 hasConceptScore W2034334356C2779091943 @default.
- W2034334356 hasConceptScore W2034334356C2779620165 @default.
- W2034334356 hasConceptScore W2034334356C2780072125 @default.
- W2034334356 hasConceptScore W2034334356C2780499067 @default.
- W2034334356 hasConceptScore W2034334356C511355011 @default.
- W2034334356 hasConceptScore W2034334356C555293320 @default.
- W2034334356 hasConceptScore W2034334356C62746215 @default.
- W2034334356 hasConceptScore W2034334356C71924100 @default.
- W2034334356 hasIssue "1" @default.
- W2034334356 hasLocation W20343343561 @default.
- W2034334356 hasOpenAccess W2034334356 @default.
- W2034334356 hasPrimaryLocation W20343343561 @default.
- W2034334356 hasRelatedWork W1539687393 @default.
- W2034334356 hasRelatedWork W1972011552 @default.
- W2034334356 hasRelatedWork W1996561303 @default.
- W2034334356 hasRelatedWork W2004682325 @default.
- W2034334356 hasRelatedWork W2007569751 @default.
- W2034334356 hasRelatedWork W2033921535 @default.
- W2034334356 hasRelatedWork W2037503208 @default.
- W2034334356 hasRelatedWork W2043425870 @default.
- W2034334356 hasRelatedWork W2072909849 @default.
- W2034334356 hasRelatedWork W2809026100 @default.
- W2034334356 hasVolume "9" @default.
- W2034334356 isParatext "false" @default.
- W2034334356 isRetracted "false" @default.
- W2034334356 magId "2034334356" @default.
- W2034334356 workType "article" @default.